Using a variety of assays for cell proliferation, cell cycle distribution, apoptosis and protein turnover/activity of BCR-ABL tyrosine kinase, the effects of imatinib on CD34+ cells from patients with CML in the megakaryocytic crisis phase were tested in the present study. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.